Jin Gohda

Title: Jin Gohda: Innovator in Anti-SARS-CoV-2 Fusion Peptides

Introduction

Jin Gohda is a notable inventor based in Kanagawa, Japan. He has made significant contributions to the field of biotechnology, particularly in the development of anti-SARS-CoV-2 fusion peptides. His work is crucial in the ongoing fight against the COVID-19 pandemic.

Latest Patents

Jin Gohda holds a patent for anti-SARS-CoV-2 fusion peptides. These peptides include sequences that correspond to the SARS-CoV-2 fusion complex heptad repeat domain HR2 and feature at least one artificial mutation. The peptides, which may be 39-mers, such as peptides #121 (SEQ ID NO: 2) and #125 (SEQ ID NO: 5), are designed to competitively bind to SARS-CoV-2. This binding action can prevent membrane-mediated SARS-CoV-2 fusion, endocytosis-mediated viral entry, or both. The administration of these peptides can inhibit or prevent SARS-CoV-2 cellular entry in subjects in need.

Career Highlights

Jin Gohda is affiliated with King Fahd University of Petroleum and Minerals, where he continues to advance his research in the field of virology and peptide technology. His innovative approach has garnered attention in the scientific community.

Collaborations

Jin collaborates with esteemed colleagues, including Mahmoud Elsayed and Mizuki Yamamoto. Their combined expertise enhances the research and development of effective therapeutic solutions.

Conclusion

Jin Gohda's work on anti-SARS-CoV-2 fusion peptides represents a significant advancement in the fight against COVID-19. His contributions are vital for developing strategies to combat viral infections and improve public health outcomes.